Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)โข Click on a phase to view related trials
Intermediate-Sized Expanded Access Study
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Registration Number
- NCT05597436
- Locations
- ๐บ๐ธ
University of California, Irvine, Orange, California, United States
๐บ๐ธGeorge Washington University, Washington D.C., District of Columbia, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05490563
- Locations
- ๐บ๐ธ
UCLA, Los Angeles, California, United States
๐บ๐ธUCHealth Neurosciences Center - Anschutz Medical Campus, Aurora, Colorado, United States
๐บ๐ธUniversity of South Florida, Tampa, Florida, United States
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: SLS-005 - Twice WeeklyDrug: SLS-005 - Once Weekly
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Registration Number
- NCT05332678
- Locations
- ๐ฆ๐บ
Austin Health, Heidelberg, Victoria, Australia
๐ฆ๐บGoulburn Valley Health, Shepparton, Victoria, Australia
๐ฆ๐บNeurodegenerative Disorders Research Pty Ltd, West Perth, Western Australia, Australia
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
- Conditions
- Depressive Disorder, MajorSuicidal
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT04669665
- Locations
- ๐บ๐ธ
Seelos Investigational Site, Morgantown, West Virginia, United States